Modification of crescentic Masugi nephritis in the rabbit by Bredinin, a new immunosuppressant.
Experiments were undertaken to ascertain whether progression of crescentic Masugi nephritis in rabbits could be prevented by the administration of Bredinin (BR). Crescentic glomerulonephritis can be induced with high reproducibility by intramuscular preimmunization on day 1, followed by intravenous injections on days 3 and 5 of nephrotoxic duck gamma-globulin (NTD gamma-gl). 30 rabbits were divided into 3 groups including controls (group 1). Two groups of 10 nephritic rabbits were each treated with 10 mg/kg of BR either after or before the development of proteinuria (groups 2 and 3). In group 3, the onset of proteinuria showed a significant delay and duration of survival was significantly prolonged, compared with controls. Serum antibody titers after day 8 and creatinine levels after day 10, as well as the initial amounts of proteinuria, were also significantly lower during treatment in group 3 than in controls. Histologically, the prominent diffuse intra- and extra-capillary proliferation with monocyte accumulations observed in the control group were markedly diminished in group 3. These results suggest that early treatment in crescentic glomerulonephritis with BR will suppress the production of humoral antibody and prevent progression of the glomerular lesions.
D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D003404:Creatinine / Q000097:blood; D005921:Glomerulonephritis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D007678:Kidney Glomerulus / Q000473:pathology; D011507:Proteinuria / Q000517:prevention & control; D011817:Rabbits; D012263:Ribonucleosides / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D012263:Ribonucleosides; C010052:mizoribine; D003404:Creatinine